Post by
snootchybootchy on May 06, 2016 1:16pm
Bought more
Bought more over the last couple days at $4.62. Seems like the market has not priced in alot of good news from the company lately such as the Bilastine approval and the successful FDA inspection of the new aspirin supply facility. I think these items have derisked this investment significantly. I hope I didn't buy too early though.
Comment by
kuatolives on May 06, 2016 2:03pm
Yeah I've started accumulating again as well. We're now at something like 4x earnings without Yosprala which could quadruple earnings in a few years. Getting cheap enough I don't mind throwing some more money at it. The market is behaving quite irrationally to the biotech industry as a whole. Time to buy.
Comment by
snootchybootchy on May 06, 2016 3:52pm
Looks like the collapse in the Endo shareprice is the cause of all the irrational selling today in the spec pharma space. Endo is yet another company that will have to sell off its assets to reduce its debt -- good news for companies like Aralez and Knight who are flush with cash.